Trial · NCT01622660

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

NCT01622660, Phase 2, Terminated, Memorial Sloan Kettering Cancer Center; results first posted 2017-08-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy. Trials, record NCT01622660. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01622660

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
NCT number: NCT01622660
Status: Terminated
Phases: Phase 2
Enrollment: 2 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Bladder Cancer
Interventions: Gemcitabine, Pazopanib
First posted: 2012-06-19
Last updated: 2017-08-22
Results first posted: 2017-08-22

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival (PFS)	2 years	Progression Free Survival will be calculated from the start of treatment until progressive disease or death. Patients who die before documented progression will be considered failures at their time of death. If the patient did not progress or die, the patient will be censored on the date of last follow-up. Response and progression will be evaluated in this study using the international criteria by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Measurable lesions: lesions that can be accurately measured in at least one dimension with longest diameter ≥ 10 mm by clinical exam or with spiral CT scan or MRI (no less than double the slice thickness and a minimum of 10mm). Malignant lymph nodes must be 15 mm in the short axis when assessed by spiral CT scan to be considered measurable. Non-measurable lesions: all other lesions (or sites of disease) including small lesions (longest diameter \< 20 mm with conventional techniques or \< 10 mm u

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival (PFS)	2 years		days	NUMBER

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Progression Free Survival (PFS)	Gemcitabine and Pazopanib		184		days

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Gemcitabine and Pazopanib	2
Overall Study	COMPLETED	Gemcitabine and Pazopanib	1
Overall Study	NOT COMPLETED	Gemcitabine and Pazopanib	1

Source ClinicalTrials.gov

Adverse events28

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Elevated ALT	Hepatobiliary disorders	Gemcitabine and Pazopanib	1	2
other	Lymphopenia	Blood and lymphatic system disorders	Gemcitabine and Pazopanib	1	2
other	Elevated Alkaline Phosphatase	Hepatobiliary disorders	Gemcitabine and Pazopanib	1	2
other	Anemia	Blood and lymphatic system disorders	Gemcitabine and Pazopanib	1	2
other	Elevated AST	Hepatobiliary disorders	Gemcitabine and Pazopanib	1	2
other	Blood Bilrubin Increased	Hepatobiliary disorders	Gemcitabine and Pazopanib	1	2
other	Constipation	Gastrointestinal disorders	Gemcitabine and Pazopanib	1	2
other	Diarrhea	Gastrointestinal disorders	Gemcitabine and Pazopanib	1	2
other	Dysgeusia	Nervous system disorders	Gemcitabine and Pazopanib	1	2
other	Fatigue	General disorders	Gemcitabine and Pazopanib	2	2

1 to 10 of 28Source ClinicalTrials.gov

See all 28 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Gemcitabine and Pazopanib	0	2
Total, other adverse events	Gemcitabine and Pazopanib	2	2
Total, serious adverse events	Gemcitabine and Pazopanib	1	2

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01622660

GET https://conductscience.org/api/trials/v1/NCT01622660/events?page=2

API reference For AI assistants